RecruitingPhase 2NCT07077551

NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm Trial

Studying Neuroendocrine neoplasm

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Intervention
NALIRIFOX(drug)
Enrollment
28 target
Eligibility
18-75 years · All sexes
Timeline
20252028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07077551 on ClinicalTrials.gov

Other trials for Neuroendocrine neoplasm

Additional recruiting or active studies for the same condition.

See all trials for Neuroendocrine neoplasm

← Back to all trials